Amanda Williams, DO
Geriatric Medicine · London, OHNPI 1104147669
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 260 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by AbbVie at 28.5% of the total. Reporting peaked in 2021 at $1,072 and has fallen 74.1% since, to $278 in 2025.
Across 260 payments — averaging $13.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$992
- Amgen$543
- Novo Nordisk$428
- Merck$216
- Johnson & Johnson$193
- Lilly USA, LLC$164
- plus $940 from 22 others
What the payments were for
- Food & beverage$3,462100%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 83 | $992 |
| Amgen | 41 | $543 |
| Novo Nordisk | 34 | $428 |
| Merck | 14 | $216 |
| Johnson & Johnson | 15 | $193 |
| Lilly USA, LLC | 11 | $164 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $130 |
| AstraZeneca | 7 | $105 |
| Boehringer Ingelheim | 8 | $104 |
| Pfizer | 6 | $88 |
| Novartis | 4 | $59 |
| Upsher-smith Laboratories LLC | 3 | $56 |
| Amarin Pharma, Inc. | 2 | $46 |
| Astellas Pharma US Inc | 2 | $39 |
| Corcept Therapeutics | 2 | $36 |
| Edwards Lifesciences | 2 | $35 |
| Teva Pharmaceuticals USA, Inc. | 2 | $32 |
| Neurocrine Biosciences, Inc. | 2 | $28 |
| Kowa Pharmaceuticals America, Inc. | 2 | $28 |
| E.r. Squibb & Sons, L.L.C. | 2 | $27 |
| Biohaven Pharmaceuticals, Inc. | 1 | $24 |
| Phathom Pharmaceuticals, Inc. | 2 | $19 |
| Avvisto Therapeutics, LLC | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Exact Sciences | 1 | $13 |
| Currax Pharmaceuticals LLC | 1 | $13 |
| Eisai Inc. | 1 | $13 |
| GSK | 1 | $11 |
How this compares
$3,477 in reported general payments places this provider in the 85th percentile of 146 geriatric medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 57 | $67,143 |
| TrulicityDulaglutide | 32 | $40,186 |
| JardianceEmpagliflozin | 25 | $33,696 |
| EliquisApixaban | 58 | $32,327 |
| MyrbetriqMirabegron | 86 | $30,393 |
| XareltoRivaroxaban | 41 | $23,552 |
| RybelsusSemaglutide | 11 | $16,176 |
| TrintellixVortioxetine Hydrobromide | 39 | $12,091 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $11,882 |
| Potassium Chloride | 269 | $7,068 |
| GemtesaVibegron | 29 | $7,044 |
| Atorvastatin Calcium | 557 | $5,558 |
| Metoprolol Succinate | 263 | $4,773 |
| Levothyroxine Sodium | 427 | $4,293 |
| Dofetilide | 21 | $4,202 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $428 | $83,31968 claims |
| Lilly USA, LLCTrulicity | $164 | $40,18632 claims |
| Boehringer IngelheimJardiance | $104 | $33,69625 claims |
| PfizerEliquis | $88 | $32,32758 claims |
| Astellas Pharma US IncMyrbetriq | $39 | $30,39386 claims |
| Johnson & JohnsonXarelto | $193 | $23,55241 claims |
| GSKBreo Ellipta, Arnuity Ellipta | $11 | $14,14435 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $130 | $12,09139 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 146 geriatric medicine providers in Ohio.
Other geriatric medicine in London
- Meenakshi PatelCenterville$644K
- Daniel CannoneWadsworth$423K
- Babak TousiCleveland$215K
- Brinder VijWest Chester$92K
- Sean CannoneCopley$74K
- Tai-Chi KwokWooster$26K
- James FidelholtzCincinnati$15K
- Rodney IsonCanal Fulton$10K
- Ronan FactoraCleveland$9K
- Gurjeet KahlonCenterville$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.